The TEAD family of transcription factors are regulated by the Hippo tumor suppressor pathway and they act by binding the co-activators YAP and TAZ that drive the transcription of genes involved in cell survival, proliferation, migration, differentiation and resistance.

Novorex Inc. has patented protein ENL (MLLT1; YEATS1) and protein AF-9 (MLLT3; AF9) inhibitors reported to be useful for the treatment of cancer.

Radionetics Oncology Inc. has discovered drugs targeting follicle-stimulating hormone (FSH) receptors reported to be useful for the diagnosis and treatment of cancer.

Translational Genomics Research Institute has found macrophage stimulating 1 receptor (MST1R; RON) inhibitors reported to be useful for the treatment of cancer, osteoporosis and osteolysis.

Researchers from the Beijing Institute of Radiation Medicine have presented the discovery of novel toll-like receptor (TLR)2/1 agonists as potential candidates for the treatment of lung cancer.

A Jaguahr Therapeutics Pte Ltd. patent describes new aryl hydrocarbon receptor (AhR) antagonists reported to be useful for the treatment of cancer.

Hotspot Therapeutics Inc. has identified new E3 ubiquitin-protein ligase CBL-B inhibitors reported to be useful for the treatment of cancer.

Prelude Therapeutics Inc. has described new CDK2/cyclin E2 and CDK4/cyclin D1 inhibitors reported to be useful for the treatment of cancer.